Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosrenol Conversion in CKD Stage 5 Dialysis Patients
NCT00452478Phase 4Terminated
- Sponsor
- Takeda
- Start
- May 2007
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of lanthanum carbonate in hyperphosphatemia, sponsored by Takeda. Primary endpoint: Percentage of subjects achieving serum phosphorus levels <= 1.78 mmol/L at 12 weeks. Started May 2007; status: terminated.
02
Drugs
lanthanum carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00452478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452478.